CN101066948B - 青藤碱催化氢化还原制备氢化青藤碱的方法 - Google Patents
青藤碱催化氢化还原制备氢化青藤碱的方法 Download PDFInfo
- Publication number
- CN101066948B CN101066948B CN2007100283388A CN200710028338A CN101066948B CN 101066948 B CN101066948 B CN 101066948B CN 2007100283388 A CN2007100283388 A CN 2007100283388A CN 200710028338 A CN200710028338 A CN 200710028338A CN 101066948 B CN101066948 B CN 101066948B
- Authority
- CN
- China
- Prior art keywords
- sinomenine
- catalyst
- hydrogenated
- catalytic hydrogenation
- coculine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 title claims abstract description 36
- 238000009903 catalytic hydrogenation reaction Methods 0.000 title claims abstract description 8
- 238000011946 reduction process Methods 0.000 title 1
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 claims abstract description 34
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 claims abstract description 26
- 229930002966 sinomenine Natural products 0.000 claims abstract description 26
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910018072 Al 2 O 3 Inorganic materials 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 4
- REKJPVUFKQYMHW-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC(C(F)(F)F)=C(C(O)=O)S1 REKJPVUFKQYMHW-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 13
- QAVNAPIOJZCYAH-ICMXQALXSA-N (1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1CC(OC)C(=O)C3 QAVNAPIOJZCYAH-ICMXQALXSA-N 0.000 abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 5
- 150000002431 hydrogen Chemical class 0.000 abstract description 3
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 229910019020 PtO2 Inorganic materials 0.000 abstract description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- HLQMDTAKJWMOOZ-CXUHLZMHSA-N CC(/C(/OC)=C\C(Cc(c(C1)ccc2OC)c2O)C1NC)=O Chemical compound CC(/C(/OC)=C\C(Cc(c(C1)ccc2OC)c2O)C1NC)=O HLQMDTAKJWMOOZ-CXUHLZMHSA-N 0.000 description 1
- PHUHOTJSRRFTRH-UHFFFAOYSA-N CN(CC1)C(C2)C(CC(C(C3)O)OC)C13c1c2ccc(OC)c1O Chemical compound CN(CC1)C(C2)C(CC(C(C3)O)OC)C13c1c2ccc(OC)c1O PHUHOTJSRRFTRH-UHFFFAOYSA-N 0.000 description 1
- QAVNAPIOJZCYAH-UHFFFAOYSA-N CN(CC1)C(Cc2ccc3OC)C(CC(C(C4)=O)OC)C14c2c3O Chemical compound CN(CC1)C(Cc2ccc3OC)C(CC(C(C4)=O)OC)C14c2c3O QAVNAPIOJZCYAH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种青藤碱催化氢化还原制备氢化青藤碱的方法,该方法包含:(1)使用10%Pd负载在活性炭上的Pd/C催化剂或PtO2催化剂,在氢气为300~500psi的压力下,反应溶剂为水或乙醇的体系中,将青藤碱催化氢化还原成二氢化青藤碱;(2)使用5%Rh负载在Al2O3粉的Rh/Al2O3催化剂,在氢气为300~500 psi的压力下,在反应溶剂为水或乙醇的体系中,将青藤碱催化氢化还原成氢化青藤碱;上述合成的氢化青藤碱经初步药理药效实验表面具有较高的生理活性。
Description
技术领域
本发明属于化学制药,具体涉及一种青藤碱催化氢化还原制备氢化青藤碱的方法。
背景技术
青藤碱是从天然中药青风藤中提取的有效生物碱单离体植物药(药用多为其盐酸盐)。青藤碱治疗类风湿性关节炎疗效确切,总有效率为85%左右,起效时间为2-3周,约1个月后有明显好转。青藤碱对治疗患者手及下肢功能、关节晨僵时间、关节疼痛、血沉及类风湿因子等改进均较显著,但使用青藤碱药物不足之处是药理作用慢,须长期服药,口服生物利用度较低,半衰期较短。特别值得指出的是,大约有1/3的患者使用青藤碱后,引起皮肤搔痒的过敏症状,限制了其应用的推广。以生物碱单离体青藤碱为母体,对青藤碱进行化学结果改性是一项具有意义的工作。本专利合成的氢化青藤碱经初步药理药效实验表面具有较高的生理活性。
发明内容
本发明的目的是提供一种青藤碱催化氢化还原制备氢化青藤碱的方法。该方法包含:
(1)使用10%Pd负载在活性炭上的Pd/C催化剂或PtO2催化剂,在氢气为300~500psi的压力下,反应溶剂为水或乙醇的体系中,将青藤碱催化氢化还原成二氢化青藤碱;如下述式I:
(2)使用5%Rh负载在Al2O3粉的Rh/Al2O3催化剂,在氢气为300~500psi的压力下,在反应溶剂为水或乙醇的体系中,将青藤碱催化氢化还原成氢化青藤碱如下述式II:
上述催化剂用量是青藤碱的0.5~2%。
上述反应温度可在室温下完成反应过程。
上述青藤碱是天然单离青藤碱或天然单离青藤碱盐酸盐。
本发明合成的氢化青藤碱经初步药理药效实验表面具有较高的生理活性。
说明书附图
图1是本发明的氢化青藤碱II的晶体结构图。
具体实施方式
下面结合实施例对本发明的技术方案作进一步的描述。
1.青藤碱纯化
(1)青藤碱盐酸盐的重结晶:取青藤碱盐酸盐(含量95%)10克,在回流下溶解于约170ml无水乙醇中,然后将溶液冷却至室温,静置,析出晶体,过滤。得白色晶体9.4克。
(2)青藤碱盐酸盐转化成青藤碱:取上制备的青藤碱盐酸盐2克,溶解于约15ml蒸馏水中(pH=7)。用15%NH3水缓慢地调溶液体系至pH=10,再用CHCl3萃取4次(30ml×4)。合并萃取液。有机相用无水K2CO3干燥约40min,过滤,旋转蒸发去溶剂,得白色固体1.7克。
2.二氢化青藤碱I的制备
在带搅拌50ml高压反应釜中,取上述制备的青藤碱1g,乙醇20ml,0.1gPd/C(10%Pd负载在活性炭)催化剂,充压氢气至350psi,在常温下反应至反应釜中压力不再降低(大约10小时),即可释放氢气,停止反应。去溶剂,即得二氢化青藤碱(1),收率100%。
3.氢化青藤碱II的制备
在带搅拌50ml高压反应釜中,取上述制备的青藤碱盐酸盐1g,去离子水15ml,0.1g Rh/Al2O3(5%Rh负载在Al2O3粉)催化剂,充压氢气至400psi,在常温下反应至反应釜中压力不再降低(大约24小时),即可释放氢气,停止反应。去溶剂,即得氢化青藤碱(2)([α]D 2011.3°(c=1,EtOH)),收率100%。
Claims (4)
2.根据权利要求1所述的方法,其特征在于:上述催化剂用量是青藤碱的0.5~2%。
3.根据权利要求1所述的方法,其特征在于:上述反应在室温下完成反应过程。
4.根据权利要求1所述的方法,其特征在于:上述青藤碱是天然单离青藤碱或以天然单离青藤碱盐酸盐替代青藤碱。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100283388A CN101066948B (zh) | 2007-05-30 | 2007-05-30 | 青藤碱催化氢化还原制备氢化青藤碱的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100283388A CN101066948B (zh) | 2007-05-30 | 2007-05-30 | 青藤碱催化氢化还原制备氢化青藤碱的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101066948A CN101066948A (zh) | 2007-11-07 |
CN101066948B true CN101066948B (zh) | 2012-01-04 |
Family
ID=38879668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100283388A Expired - Fee Related CN101066948B (zh) | 2007-05-30 | 2007-05-30 | 青藤碱催化氢化还原制备氢化青藤碱的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101066948B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9562014B2 (en) | 2009-07-16 | 2017-02-07 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
US10363251B2 (en) | 2009-07-16 | 2019-07-30 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
PL2453895T3 (pl) * | 2009-07-16 | 2018-10-31 | Mallinckrodt Llc | (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3166560A (en) * | 1965-01-19 | G-vlkylmorpiiinan derivatives |
-
2007
- 2007-05-30 CN CN2007100283388A patent/CN101066948B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3166560A (en) * | 1965-01-19 | G-vlkylmorpiiinan derivatives |
Non-Patent Citations (3)
Title |
---|
叶仙蓉等.青藤碱衍生物的合成及其抗炎镇痛活性.药学学报39 3.2004,39(3),180-183. |
叶仙蓉等.青藤碱衍生物的合成及其抗炎镇痛活性.药学学报39 3.2004,39(3),180-183. * |
姜麟忠.催化氢化在有机合成中的应用.《催化氢化在有机合成中的应用》.1987,56-57. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9562014B2 (en) | 2009-07-16 | 2017-02-07 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101066948A (zh) | 2007-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101066948B (zh) | 青藤碱催化氢化还原制备氢化青藤碱的方法 | |
CN107641128B (zh) | 一种高效提取河豚毒素的方法 | |
Rocha et al. | Nano-based drug delivery systems used as vehicles to enhance polyphenols therapeutic effect for diabetes mellitus treatment | |
CN102875562B (zh) | 制备补骨脂素和异补骨脂素或包含它们的提取物的方法 | |
CN113717060A (zh) | 一种去甲肾上腺素及其重酒石酸盐的合成方法 | |
US8569492B2 (en) | Method for preparing halofuginone derivative | |
WO2006005112A1 (en) | Process for the synthesis of hydromorphone | |
CN119258144B (zh) | 一种提高睡眠质量的组合物及其制备方法和应用 | |
CN101054400A (zh) | 一种新人参二醇及其衍生物、其制备方法及其医药用途 | |
CN105837658A (zh) | 一种阿加曲班的合成方法 | |
CN1355172A (zh) | 从楤木总皂苷中提取齐墩果酸-3-0-β-D吡喃葡萄糖醛酸苷的方法及用途 | |
WO2020057028A1 (zh) | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 | |
CN101492480A (zh) | 2-(4-β-D-吡喃阿洛糖苷-苯基)-4,5-二芳基咪唑的合成方法 | |
CN110713471A (zh) | 一种盐酸曲美他嗪的合成方法 | |
CN102875499B (zh) | 3-氨甲基氧杂环丁烷及其有机酸盐的制备方法 | |
CN1806831B (zh) | 一种治疗银屑病的药物及其制备方法 | |
JP2023552292A (ja) | βアドレナリンアゴニスト及びその使用方法 | |
CN114276261B (zh) | 一种普鲁卡因的制备方法 | |
CN102206164A (zh) | 一种他喷他多中间体的制备方法 | |
CN102603852A (zh) | 一种雷公藤红素的制备方法 | |
CN111228253A (zh) | 九翅豆蔻提取物在制备α-葡萄糖苷酶抑制剂药物中的应用 | |
CN1039198C (zh) | 一种二萜生物碱的制备方法 | |
CN116239529B (zh) | 一种二氧化碳参与的n-甲基四氢喹啉类生物碱的制备方法 | |
CN1293038C (zh) | (1r,2s)-(-)-麻黄碱或其盐酸盐的制备方法 | |
CN116983266B (zh) | 一种二氢大麻二酚二呋喃甲酸酯的包埋体系及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20130530 |